Resveratrol triggers autophagy‐related apoptosis to inhibit the progression of colorectal cancer via inhibition of FOXQ1
Phytotherapy Research · 2024
DOI: 10.1002/ptr.8184 ↗At a glance
Journal article in Phytotherapy Research, 2024. Written by MinFeng Zhou and 8 co-authors. Institution: Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Major MEDLINE topics: Resveratrol, Colorectal Neoplasms, Apoptosis, Autophagy. Cited 25 times so far (Crossref); 49 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province, Subject of Wuhan Health and Family Planning Commission.
Abstract (original language)
Colorectal cancer (CRC) is a significant health problem with elevated mortality rates, prompting intense exploration of its complex molecular mechanisms and innovative therapeutic avenues. Resveratrol (RSV), recognised for its anticancer effects through SIRT1 activation, is a promising candidate for CRC treatment. This study focuses on elucidating RSV's role in CRC progression, particularly its effect on autophagy‐related apoptosis. Using bioinformatics, protein imprinting and immunohistochemistry, we established a direct correlation between FOXQ1 and adverse CRC prognosis. Comprehensive in vitro experiments confirmed RSV's ability to promote autophagy‐related apoptosis in CRC cells. Plasmids for SIRT1 modulation were used to investigate underlying mechanisms. Molecular docking, glutathione‐S‐transferase pull‐down experiments and immunoprecipitation highlighted RSV's direct activation of SIRT1, resulting in the inhibition of FOXQ1 expression. Downstream interventions identified ATG16L as a crucial autophagic target. In vivo and in vitro studies validated RSV's potential for CRC therapy through the SIRT1/FOXQ1/ATG16L pathway. This study establishes RSV's capacity to enhance autophagy‐related cell apoptosis in CRC, positioning RSV as a prospective therapeutic agent for CRC within the SIRT1/FOXQ1/ATG16L pathway.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- School of Food Science and Technology, Huazhong Agricultural University, Wuhan, China.
- Department of Gastrointestinal Surgery, Enshi Central Hospital, Enshi City, China.
- School of Acupuncture and Bone Injury, Hubei University of Chinese Medicine, Wuhan, China.
ORCID profiles: Rui Chen
Funding
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
- Subject of Wuhan Health and Family Planning Commission
Cite
APA
Zhou, M., Niu, H., Cui, D., Huang, G., Li, J., Tian, H., Xu, X., Liang, F., & Chen, R. (2024). Resveratrol triggers autophagy‐related apoptosis to inhibit the progression of colorectal cancer via inhibition of FOXQ1. Phytotherapy Research. https://doi.org/10.1002/ptr.8184
Vancouver
Zhou M, Niu H, Cui D, Huang G, Li J, Tian H, et al. Resveratrol triggers autophagy‐related apoptosis to inhibit the progression of colorectal cancer via inhibition of FOXQ1. Phytotherapy Research. 2024. doi:10.1002/ptr.8184
BibTeX
@article{Zhou2024,
author = {Zhou, MinFeng and Niu, HuiFang and Cui, DanDan and Huang, GuoQuan and Li, JinXiao and Tian, HaoRan and Xu, XiaoJuan and Liang, FengXia and Chen, Rui},
title = {Resveratrol triggers autophagy‐related apoptosis to inhibit the progression of colorectal cancer via inhibition of FOXQ1},
journal = {Phytotherapy Research},
year = {2024},
doi = {10.1002/ptr.8184}
}
EUVIMED